According to TipRanks, Matteis is a 5-star analyst with an average return of 16.7% and a 52.83% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA Pharmaceuticals, and Alkermes.
In addition to Stifel Nicolaus, Ionis Pharmaceuticals also received a Hold from Goldman Sachs’s Salveen Richter in a report issued on July 29. However, on July 30, Morgan Stanley maintained a Buy rating on Ionis Pharmaceuticals (NASDAQ: IONS).
Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $267.95 million and a GAAP net loss of $114.65 million. In comparison, last year the company earned a revenue of $452.05 million and had a net profit of $123.55 million
Based on the recent corporate insider activity of 177 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IONS in relation to earlier this year.
